CareDx, Inc (CDNA)
USD 15.0
(-0.46%)
USD 15.0
(-0.46%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -101.9 Million USD | -31.94% |
| 2022 | -77.23 Million USD | -159.81% |
| 2021 | -29.72 Million USD | -67.8% |
| 2020 | -17.71 Million USD | 27.79% |
| 2019 | -24.53 Million USD | -57.48% |
| 2018 | -15.57 Million USD | 23.24% |
| 2017 | -20.29 Million USD | 45.64% |
| 2016 | -37.33 Million USD | -212.87% |
| 2015 | -11.93 Million USD | -1054.56% |
| 2014 | 1.25 Million USD | 245.86% |
| 2013 | -857 Thousand USD | 63.41% |
| 2012 | -2.34 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -10.49 Million USD | -160.35% |
| 2024 Q2 | -4.03 Million USD | 79.16% |
| 2024 Q1 | -19.33 Million USD | 18.97% |
| 2023 Q1 | -24.32 Million USD | -27.22% |
| 2023 Q2 | -27.62 Million USD | -13.57% |
| 2023 Q4 | -23.86 Million USD | 17.09% |
| 2023 Q3 | -28.78 Million USD | -4.2% |
| 2023 FY | -101.9 Million USD | -31.94% |
| 2022 Q4 | -19.12 Million USD | -10.27% |
| 2022 FY | -77.23 Million USD | -159.81% |
| 2022 Q1 | -19.05 Million USD | -23.73% |
| 2022 Q2 | -21.71 Million USD | -13.99% |
| 2022 Q3 | -17.33 Million USD | 20.17% |
| 2021 FY | -29.72 Million USD | -67.8% |
| 2021 Q1 | -858 Thousand USD | 72.02% |
| 2021 Q4 | -15.39 Million USD | -76.45% |
| 2021 Q3 | -8.72 Million USD | -84.04% |
| 2021 Q2 | -4.74 Million USD | -452.68% |
| 2020 Q2 | -10.8 Million USD | -87.85% |
| 2020 FY | -17.71 Million USD | 27.79% |
| 2020 Q1 | -5.75 Million USD | -3.72% |
| 2020 Q4 | -3.06 Million USD | -5.5% |
| 2020 Q3 | -2.9 Million USD | 73.09% |
| 2019 Q4 | -5.54 Million USD | 17.82% |
| 2019 Q2 | -6.84 Million USD | -26.83% |
| 2019 FY | -24.53 Million USD | -57.48% |
| 2019 Q1 | -5.39 Million USD | -123.44% |
| 2019 Q3 | -6.74 Million USD | 1.42% |
| 2018 Q4 | -2.41 Million USD | 11.18% |
| 2018 FY | -15.57 Million USD | 23.24% |
| 2018 Q3 | -2.71 Million USD | 47.8% |
| 2018 Q2 | -5.2 Million USD | 0.5% |
| 2018 Q1 | -5.23 Million USD | -22.11% |
| 2017 Q1 | -8.54 Million USD | 54.7% |
| 2017 FY | -20.29 Million USD | 45.64% |
| 2017 Q4 | -4.28 Million USD | -10.95% |
| 2017 Q3 | -3.86 Million USD | -7.36% |
| 2017 Q2 | -3.59 Million USD | 57.88% |
| 2016 Q2 | -6.84 Million USD | -4.26% |
| 2016 Q1 | -6.56 Million USD | -47.22% |
| 2016 FY | -37.33 Million USD | -212.87% |
| 2016 Q3 | -4.93 Million USD | 27.97% |
| 2016 Q4 | -18.86 Million USD | -282.34% |
| 2015 Q1 | -1.39 Million USD | -424.24% |
| 2015 FY | -11.93 Million USD | -1054.56% |
| 2015 Q4 | -4.46 Million USD | -39.74% |
| 2015 Q3 | -3.19 Million USD | -10.64% |
| 2015 Q2 | -2.88 Million USD | -107.48% |
| 2014 FY | 1.25 Million USD | 245.86% |
| 2014 Q2 | -345 Thousand USD | -51.98% |
| 2014 Q4 | 429 Thousand USD | -69.2% |
| 2014 Q3 | 1.39 Million USD | 503.77% |
| 2014 Q1 | -227 Thousand USD | -144.6% |
| 2013 Q3 | -332 Thousand USD | -29.69% |
| 2013 Q1 | -778 Thousand USD | 0.0% |
| 2013 FY | -857 Thousand USD | 63.41% |
| 2013 Q2 | -256 Thousand USD | 67.1% |
| 2013 Q4 | 509 Thousand USD | 253.31% |
| 2012 FY | -2.34 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -4.666% |
| Biodesix, Inc. | -41.34 Million USD | -146.481% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -1178.027% |
| Castle Biosciences, Inc. | -67.97 Million USD | -49.904% |
| DarioHealth Corp. | -56.18 Million USD | -81.352% |
| Exact Sciences Corporation | -215.01 Million USD | 52.607% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 109.288% |
| Illumina, Inc. | -1.06 Billion USD | 90.468% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -890.939% |
| iSpecimen Inc. | -11.16 Million USD | -812.318% |
| Standard BioTools Inc. | -76.6 Million USD | -33.029% |
| 23andMe Holding Co. | -321.35 Million USD | 68.291% |
| Medpace Holdings, Inc. | 336.82 Million USD | 130.253% |
| NeoGenomics, Inc. | -107.73 Million USD | 5.417% |
| Inotiv, Inc. | -81.46 Million USD | -25.092% |
| Psychemedics Corporation | -2.92 Million USD | -3388.531% |
| Prenetics Global Limited | -52.51 Million USD | -94.045% |
| Precipio, Inc. | -7.62 Million USD | -1237.27% |
| RadNet, Inc. | 98.69 Million USD | 203.245% |
| Sotera Health Company | 276.69 Million USD | 136.828% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -2244.685% |
| Exagen Inc. | -22.83 Million USD | -346.206% |
| Natera, Inc. | -446.24 Million USD | 77.165% |
| Aspira Women's Health Inc. | -18.85 Million USD | -440.526% |
| Neogen Corporation | 58.66 Million USD | 273.704% |
| Myriad Genetics, Inc. | -123.7 Million USD | 17.623% |
| ICON Public Limited Company | 956.15 Million USD | 110.657% |
| Bionano Genomics, Inc. | -215.24 Million USD | 52.659% |
| Check-Cap Ltd. | -19.28 Million USD | -428.335% |
| Twist Bioscience Corporation | -220.83 Million USD | 53.856% |
| Guardant Health, Inc. | -564.72 Million USD | 81.956% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -3828.92% |
| Fulgent Genetics, Inc. | -72.69 Million USD | -40.175% |
| Sera Prognostics, Inc. | -39.82 Million USD | -155.895% |
| OPKO Health, Inc. | -157.02 Million USD | 35.104% |
| Personalis, Inc. | -109.93 Million USD | 7.31% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -830.314% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -2244.685% |
| MDxHealth SA | -27.32 Million USD | -272.891% |
| Prenetics Global Limited | -52.51 Million USD | -94.045% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -868.564% |
| Mainz Biomed B.V. | -26.64 Million USD | -282.44% |
| Trinity Biotech plc | -27.04 Million USD | -276.779% |
| Neuronetics, Inc. | -30.55 Million USD | -233.508% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -1178.027% |